ocrevus.com — September 2026 traffic, keywords & AI visibility

ocrevus.com draws an estimated 14,000 visits a month from search engines. Effectively all of it is organic — about 13,900 visits from unpaid results. Paid search contributes only about 17 visits a month. Spread across 210 ranking keywords, that averages roughly 66 organic visits per keyword.

On our AI visibility scale ocrevus.com earns 67 of 100 points, a grade C. It takes full marks for LLMS.txt and Structured data. The biggest gap is SEO health, at 0 of 20 points (0/100), worth 20 points if closed. It also loses points on Crawlability (0/10) and Company profile (22/25).

The llms.txt on ocrevus.com runs to 81 lines (4,352 characters) across 12 sections, last generated in May 2026. It introduces the site as "Ocrevus® (ocrelizumab) | Multiple Sclerosis (MS) Treatment". It tells AI engines the business works in Biotechnology, Pharmaceuticals and Neurology. It describes 5 products, with prices such as Ocrevus ENLIGHTEN Study Data at Free for HCPs. Services it lists include MS Patient Navigation, Infusion Center Locator, Cost and Coverage Assistance and Safety Information Resources. The audience it names is MS patients, neurologists, healthcare providers, aged Adults 18-65 (Global). Technologies it mentions include HTTPS and Viewport Optimized. The keywords it claims start with "Ocrevus", "ocrelizumab", "multiple sclerosis" and "MS treatment". It gives the company type as Public.

# Ocrevus® (ocrelizumab) | Multiple Sclerosis (MS) Treatment

## About
Ocrevus delivers targeted B-cell therapy for multiple sclerosis patients facing relapsing or primary progressive forms of the disease. This monoclonal antibody treatment, given every six months by infusion, significantly cuts relapse rates and slows disability progression based on landmark clinical trials. It fills a critical gap for primary progressive MS where options were scarce before its arrival. Neurologists prescribe it widely due to strong efficacy data across patient groups, including treatment switchers. Comprehensive support covers cost assistance, safety monitoring, and educational resources in multiple languages. Long-term studies affirm its safety with manageable risks like infections or infusion reactions. The therapy enhances patient independence through better mobility and cognitive preservation. Global availability expands access via partnerships with healthcare systems everywhere. Ongoing research explores expanded uses while refining delivery methods. Ocrevus reshapes MS management, prioritizing sustained disease control and quality of life improvements. Its unified approach across MS types simplifies care decisions for providers. Patient testimonials highlight real-world benefits beyond trial settings. Advocacy efforts boost early diagnosis and treatment adherence. Innovation in biologic

Google lists ocrevus.com for about 210 keywords, which together bring an estimated 13,900 organic visits a month.

The latest technical audit of ocrevus.com scored 0 out of 100 overall. The audit makes 8 recommendations in all.

Ocrevus's company profile names https://www.tevausa.com, https://www.biogen.com, https://www.merck.com and https://www.novartis.com as competitors. Its own llms.txt adds https://www.abbvie.com and https://www.sanofi.com. Outside its market, the domains ranked closest to it in our worldwide ranking are crea-sc.org.br, wan64.de, vgckb0300n.com and schoolzineplus.com.

https://www.tevausa.com

https://www.biogen.com

https://www.merck.com

https://www.novartis.com

https://www.abbvie.com

https://www.sanofi.com